



UK Health
Security
Agency

By email

cj-editor@biggeesblog.cymru]

Our ref: 07/12/21/kl/1909

23 December 2021

Dear Wynne Jones,

Re: CJ 216 - Myocarditis and Pericarditis following Covid 19 vaccination

Thank you for your request received on 7 December 2021 addressed to the UK Health Security Agency (UKHSA). In accordance with Section 1(1)(a) of the Freedom of Information Act 2000 (the Act), I can confirm that UKHSA does hold the information you have specified.

Request

I note from attached document - published on Gov.UK 7 December 2021 - that UKHSA has issued new clinical guidance to healthcare professionals to support the detection and management of clinical cases of Myocarditis and Pericarditis associated with the roll-out of the experimental mRNA Covid 19 vaccines. I would be grateful if you could arrange to provide me with the following information from your records.

Brief details of the investigations now underway by UKHSA - in conjunction with your medical regulator MHRA - to establish linkage between cases of Myocarditis and Pericarditis and the roll-out of experimental mRNA Covid 19 vaccines.

Cases are now being reported in UK, Europe and America. As you are no doubt aware, links to official vaccine adverse reaction monitoring systems in UK [MHRA yellow card], Europe [EudraVigilance reporting / monitoring system] and America [VAERS, Vaccine Adverse Event Reporting System] are available as set out below.

MHRA

<https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions>

EudraVigilance

<https://www.ema.europa.eu/en/human-regulatory/research-development/pharmacovigilance/eudravigilance>

VAERS

<https://vaers.hhs.gov/data.html>

VAERS data analysis site [with pdf download report]

<http://vaersanalysis.info/2021/10/01/vaers-summary-for-covid-19-vaccines-through-9-24-2021/>

I look forward to receiving brief details of the investigation now underway at your convenience. Thank you.

Response

In accordance with Section 1(1)(a) of the Act, UKHSA can confirm that it does hold the information requested. However, the information is exempt under Section 21 of the Act because it is reasonably accessible by other means, and the terms of the exemption mean that we do not have to consider whether or not it would be in the public interest for you to have the information. For your convenience we have included the following link to section 4 of the Vaccine Surveillance Strategy, which provides details of the investigations underway by UKHSA (formerly PHE):

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/974300/COVID-19_vaccine_surveillance_strategy_March21.pdf

If you have any queries regarding the information that has been supplied to you, please refer your query to the Information Rights Team in writing in the first instance. If you remain dissatisfied and would like to request an internal review, then please contact us at the address above or by emailing InformationRights@UKHSA.gov.uk.

Please note that you have the right to an independent review by the Information Commissioner's Office (ICO) if a complaint cannot be resolved through the UKHSA complaints procedure. The ICO can be contacted by calling the ICO's helpline on 0303 123 1113, visiting the ICO's website at www.ico.org.uk or writing to the ICO at Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

Yours sincerely
Information Rights Team